2017 Press Releases

Webcast ImageWebcast
AVEO Oncology at the Piper Jaffray 29th Annual Healthcare Conference (Replay)
11/28/17 at 10:00 a.m. ET
AVEO Oncology at the Piper Jaffray 29th Annual Healthcare Conference
Tuesday, November 28, 2017 10:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/07/17AVEO Oncology Announces Clinical Updates to Tivozanib and Ficlatuzumab Programs
- Enrollment complete in Phase 2 portion of Phase 1/2 TiNivo trial; Next data presentation expected at 2018 Genitourinary Cancers Symposium in February 2018- - Investigator-sponsored studies of ficlatuzumab initiated in HNSCC and Pancreatic Cancer - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 7, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced clinical updates for two of its oncology programs: FOTIVDA® (tivozanib), the Company’s ... 
Printer Friendly Version
11/20/17AVEO Announces Appointment of Nikhil Mehta, Ph.D., as Senior Vice President of Regulatory and Quality Assurance
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 20, 2017-- AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Nikhil Mehta, Ph.D., as Senior Vice President of Regulatory and Quality Assurance, effective November 20, 2017. In this role, Dr. Mehta will oversee all aspects of regulatory, quality and technical operations for the company’s portfolio. Dr. Mehta brings to AVEO more than 25 years of experience in the biotechnology and pharmaceutical industr... 
Printer Friendly Version
11/15/17EUSA Pharma and AVEO Oncology Announce the First Commercial Launch of FOTIVDA® (tivozanib)
HEMEL HEMPSTEAD, England & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 15, 2017-- EUSA Pharma and AVEO Oncology (NASDAQ:AVEO) today announced the first commercial launch of FOTIVDA® (tivozanib) with the initiation of product sales in Germany. In the European Union, Norway and Iceland, tivozanib is indicated for the first line treatment of adult patients with advanced renal cell carcinoma (aRCC) and for adult patients who are vascular endothelial growth f... 
Printer Friendly Version
11/08/17AVEO Oncology to Present at Upcoming Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 8, 2017-- AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will be presenting at the following investor conferences: Jefferies 2017 London Healthcare Conference on Wednesday, November 15, 2017 at 4:00 p.m. Greenwich Mean Time. The conference is being held at the Waldorf Hilton Hotel in London. Piper Jaffray 29th A... 
Printer Friendly Version
11/07/17AVEO Reports Third Quarter 2017 Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 7, 2017-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter ended September 30, 2017 and provided a business update. “The third quarter was a transformative period for AVEO, with the achievement of significant milestones in each of the three pillars of our global strategy for tivozanib. Notably, with the European approval of tivozanib (FOTIVDA®) in advanced RCC, we have tran... 
Printer Friendly Version
11/06/17AVEO Oncology and EUSA Pharma Announce Promising Phase 1 Results from the Phase 1/2 TiNivo Study of Tivozanib and Nivolumab in Renal Cell Carcinoma
Oral Presentation Delivered at the 16th International Kidney Cancer Symposium CAMBRIDGE, Mass. & HEMEL HEMPSTEAD, England--(BUSINESS WIRE)--Nov. 6, 2017-- AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma today announced the presentation of promising results from the ongoing Phase 1 portion of the TiNivo study, a Phase 1/2 multicenter trial of tivozanib (FOTIVDA®) in combination with Bristol-Myers Squibb’s nivolumab (OPDIVO®), an immune checkpoi... 
Printer Friendly Version
10/16/17AVEO Oncology Announces Phase 1 Results from TiNivo Study to be Presented at the 16th International Kidney Cancer Symposium
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 16, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced that results from the Phase 1 portion of the Phase 1/2 TiNivo study will be presented in an oral presentation at the 16th International Kidney Cancer Symposium, to be held November 3-4, 2017 in Miami. The TiNivo trial is a Phase 1/2 multicenter trial of FOTIVDA® (tivozanib) in combination with Bristol-Myers Squibb’s OPDIVO® (nivolumab), an immune checkpo... 
Printer Friendly Version
10/05/17AVEO Oncology Announces Completion of TIVO-3 Study Futility Analysis with No Changes to Study Protocol
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 5, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced the completion of a pre-planned futility analysis of the Phase 3 TIVO-3 trial, the Company’s randomized, controlled, multi-center, open-label study to compare FOTIVDA® (tivozanib) to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC). Based on the results of the futility analysis, which was reviewed by an independent statistician, the stud... 
Printer Friendly Version
09/20/17AVEO Oncology and EUSA Pharma Announce TiNivo Combination Study Opt-in
Exercise of Option Triggers $2.0 Million Research and Development Payment to AVEO CAMBRIDGE, Mass. & HEMEL HEMPSTEAD, England--(BUSINESS WIRE)--Sep. 20, 2017-- AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma today announced that EUSA Pharma, under its multi-territory licensing agreement with AVEO for FOTIVDA® (tivozanib), has opted into the Phase 1/2 TiNivo study. Under terms of the agreement, EUSA may utilize data from the study for regulator... 
Printer Friendly Version
09/13/17AVEO Oncology Announces Receipt of Payments from EUSA Pharma and CANbridge
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 13, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced the receipt of a $4 million research and development payment from EUSA Pharma related to the approval of FOTIVDA® (tivozanib) for the treatment of adult patients with advanced renal cell carcinoma in Europe, and a $0.5 million milestone payment from CANbridge related to manufacturing development activities for AV-203, AVEO’s clinical-stage ErbB3 (HER3) i... 
Printer Friendly Version
09/05/17AVEO Oncology to Present at Upcoming Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 5, 2017-- AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will be presenting at the following investor conferences: The 19th Annual Rodman & Renshaw Global Investment Conference on Tuesday, September 12, 2017 at 9:35 a.m. Eastern Time. The conference is being held at the Lotte New York Palace Hotel. The Canto... 
Printer Friendly Version
08/28/17AVEO Oncology Announces FOTIVDA® (tivozanib) Approved in the European Union for the Treatment of Advanced Renal Cell Carcinoma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 28, 2017-- AVEO Oncology (NASDAQ: AVEO) today announced that the European Commission (EC) has approved FOTIVDA® (tivozanib) for the treatment of adult patients with advanced renal cell carcinoma (RCC) in the European Union plus Norway and Iceland. Tivozanib is indicated for the first line treatment of adult patients with advanced RCC and for adult patients who are vascular endothelial growth factor receptor ... 
Printer Friendly Version
08/09/17AVEO Reports Second Quarter 2017 Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 9, 2017-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the second quarter ended June 30, 2017, and provided a business update. “The second quarter was marked by validating events in each of the three pillars of our global tivozanib strategy: a recommendation for approval of tivozanib in advanced renal cell carcinoma (RCC) by the CHMP, reaching our enrollment target for the Phase 3 TIVO-3... 
Printer Friendly Version
06/27/17AVEO Oncology Announces $14M in Aggregate Gross Proceeds from Hercules Credit Facility and At-the-market Stock Offerings
Additional Resources Sufficient to Fund Planned Operations into the 4Q 2018 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 27, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced that it has secured $14 million in aggregate gross proceeds through its credit facility with Hercules Capital, Inc. (Hercules) and the sale of common stock via its at-the-market issuance sales agreement with FBR & Co. (FBR). Pursuant to its 2010 loan and security ... 
Printer Friendly Version
06/23/17AVEO Oncology Announces Positive CHMP Opinion for Tivozanib as a Treatment of Advanced Renal Cell Carcinoma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 23, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has recommended FOTIVDA™ (tivozanib) for approval as a treatment for patients with advanced renal cell carcinoma (RCC). The CHMP's recommendation is now referred to the European Commission (EC). The EC, which typically adheres to the ... 
Printer Friendly Version
06/20/17AVEO Oncology Announces Pivotal Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma Reaches Enrollment Target
– Pre-planned futility analysis of the trial expected midyear 2017; topline data expected in the first quarter of 2018 – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 20, 2017-- AVEO Oncology (NASDAQ: AVEO) today announced that the Company’s pivotal TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC) has reached its enrollment targ... 
Printer Friendly Version
06/08/17AVEO Oncology Announces Phase 1/2 TiNivo Trial of Tivozanib and Opdivo® (nivolumab) in RCC Advances to Phase 2
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 8, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced that its Phase 1/2 AVEO-sponsored TiNivo trial evaluating tivozanib in combination with Bristol-Myers Squibb’s anti-PD-1 therapy, Opdivo® (nivolumab), in subjects with advanced renal cell carcinoma (RCC) has progressed to the Phase 2 portion of the trial. Advancement of the study into the Phase 2 expansion follows the successful completion of the ... 
Printer Friendly Version
06/05/17AVEO Oncology and Biodesix Announce Results from Two Investigator-Sponsored Phase 1 Studies of HGF Targeted Antibody Ficlatuzumab at the 2017 ASCO Annual Meeting
Announce Expected Initiation of an Investigator-Initiated, Randomized, Phase 2, Multicenter Trial of Ficlatuzumab and Cetuximab in HNSCC in 2H 2017 AVEO Announces Trial in Progress Poster Also Presented Highlighting Phase 3 TIVO-3 Study of Tivozanib in RCC CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 5, 2017-- AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc., co-development partners, today announced the presentation of results from t... 
Printer Friendly Version
05/19/17AVEO Oncology Announces Completion of a CHMP Oral Explanation for Tivozanib as a Treatment of First-Line Renal Cell Carcinoma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 19, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced its European licensee for tivozanib, EUSA Pharma, has completed an oral explanation to the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), as part of the Marketing Authorization Application (MAA) review process for tivozanib as a treatment for patients with first-line renal cell carcinoma (R... 
Printer Friendly Version
05/16/17AVEO Announces Appointment of Matthew Dallas as Chief Financial Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 16, 2017-- AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Matthew Dallas as chief financial officer, effective June 1, 2017. In this role, Mr. Dallas will be responsible for the Company’s financial strategy and management as it takes steps toward the potential commercialization of tivozanib. Mr. Dallas will also serve on the executive leadership team which governs corporate strategy at AVEO. He succ... 
Printer Friendly Version
05/15/17AVEO Issues Statement Regarding the Passing of Lead Director Henri A. Termeer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 15, 2017-- The Board of Directors of AVEO Oncology (NASDAQ:AVEO) today issued the following statement regarding the passing of its Lead Director Henri A. Termeer. “We are deeply saddened at the loss of a visionary, mentor, colleague and dear friend, Henri A. Termeer. Henri’s wisdom, foresight and persistence fundamentally changed our industry, which exists to serve patients suffering from devastating ... 
Printer Friendly Version
05/08/17AVEO Oncology Announces Receipt of USPTO Notice of Allowance Related to AV-353
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 8, 2017-- AVEO Oncology (NASDAQ: AVEO) today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 14/653,684, entitled "notch binding agents and antagonists and methods of use thereof." Allowed under the application are composition of matter and method of use claims related to the Company's humanized anti-Notch 3 antibodies, in... 
Printer Friendly Version
05/04/17AVEO Reports First Quarter 2017 Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 4, 2017-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2017, and provided a business update. “We strengthened our balance sheet in the first quarter through an underwritten public offering, giving us the resources to potentially fund operations through the readout of our pivotal, Phase 3 TIVO-3 study of tivozanib in renal cell cancer (RCC), expected in th... 
Printer Friendly Version
04/20/17AVEO Announces Presentations at the 2017 ASCO Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 20, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced that poster presentations for three clinical studies will be presented at the upcoming 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2-6, 2017. Among these is a Trials in Progress presentation highlighting the ongoing Phase 3, randomized, controlled, multi-center, open-label TIVO-3 study comparing tivozanib, the Comp... 
Printer Friendly Version
04/13/17AVEO Announces Submission of Response to Tivozanib Marketing Authorization Application Day 180 List of Outstanding Issues
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 13, 2017-- AVEO Oncology (NASDAQ: AVEO) today announced that its European licensee for tivozanib, EUSA Pharma, has submitted responses to the European Medicines Agency (EMA) Day 180 List of Outstanding Issues (LOI) related to the Marketing Authorization Application (MAA) for tivozanib as a first-line treatment for renal cell carcinoma. With submission of the response complete, EUSA remains tentatively scheduled to ... 
Printer Friendly Version
04/03/17AVEO Announces Milestone Payment from CANbridge for AV-203
Company Provides Updated Financial Guidance CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 3, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced receipt of a $500,000 milestone payment from CANbridge Life Sciences Ltd., a biopharmaceutical company focused on developing western drug candidates in China and North Asia, related to a technology transfer milestone for AV-203, AVEO’s clinical-stage ErbB3 (HER3) inhibitory antibody candidate. AV-203 has dem... 
Printer Friendly Version
03/31/17AVEO Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 31, 2017-- AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) today announced the closing of its previously announced underwritten public offering of 34,500,000 shares of common stock, including the exercise in full by the underwriter of its option to purchase 4,500,000 shares at the public offering price of $0.50 per share. The exercise of the option increased the amount of net proceeds raised in the offering, after underwr... 
Printer Friendly Version
03/28/17AVEO Announces Pricing of $15.0 Million Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 28, 2017-- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it has priced an underwritten public offering of 30,000,000 shares of common stock at a price to the public of $0.50 per share, before underwriting discounts, which would result in aggregate gross proceeds of approximately $15 million. All of the shares in the offering are to be sold by AVEO. AVEO has also granted the underwriter a 30-day opt... 
Printer Friendly Version
03/28/17AVEO Announces Proposed Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 28, 2017-- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares in the offering are to be sold by AVEO. ... 
Printer Friendly Version
03/22/17AVEO Reports Full Year 2016 Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 22, 2017-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2016 and provided a business update. “TIVO-3, our lead clinical program designed to serve as the basis for a potential U.S. registration for tivozanib as a first- and third-line treatment for renal cell cancer, continues to enroll ahead of schedule and has now completed its first safety review,” said... 
Printer Friendly Version
03/22/17AVEO Announces First Patient Dosed in Phase 1/2 TiNivo Trial of Tivozanib and Opdivo® (nivolumab) in Advanced RCC
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 22, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced that the first patient has been dosed in the Phase 1/2 AVEO-sponsored TiNivo trial evaluating tivozanib in combination with Bristol-Myers Squibb’s anti-PD-1 therapy, Opdivo® (nivolumab), in advanced renal cell carcinoma (RCC). The study, which will be led by the Institut Gustave Roussy in Paris, is under the direction of Professor Bernard Escudier, MD, Chairman... 
Printer Friendly Version
02/23/17AVEO Announces TIVO-3 Passes The First Safety Monitoring Committee Safety Review
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 23, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced that its pivotal, Phase 3 TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC), has successfully completed the first safety review by the study’s Safety Monitoring Committee (SMC). The SMC concluded that no safety concern was observed for tivozani... 
Printer Friendly Version
02/09/17AVEO Announces Clinical and Regulatory Updates for Tivozanib
- Pivotal TIVO-3 Trial Enrollment Proceeding Substantially Ahead of Schedule; Enrollment Completion Expected in June - - Phase 1/2 TiNivo Trial Sites Scheduled to Open for Enrollment in Early March - - Partner EUSA Pharma Receives Day 180 List of Outstanding Issues from EMA, Oral Explanation Expected in 2Q 2017 - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 9, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced clinical and regulator... 
Printer Friendly Version
02/06/17AVEO to Present at the 19th Annual BIO CEO & Investor Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 6, 2017-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael Needle, M.D., Chief Medical Officer, will present at the 19th Annual BIO CEO & Investor Conference on Monday, February 13, 2017 at 8:30 AM E.T. at the Waldorf Astoria Hotel in New York City. A live webcast can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast wi... 
Printer Friendly Version